UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial

Anna Brandt, Konrad Klinghammer, Christoph Schultheiss, Lisa Paschold, Claudia Wickenhauser, Marcus Bauer, Anna Bergqvist, Dennis Hahn, Philippe Schafhausen, Mareike Tometten, Markus Blaurock, Henrike Barbara Zech, Chia-Jung Busch, Andreas Dietz, Urs Müller-Richter, Jürgen Alt, Andreas Boehm, Simone Kowoll, Jörg Steighardt, Alexander Lasch, Ingunn Hagen Westgaard, Marita Westhrin, Alexander Stein, Axel Hinke, Mascha Binder
doi: https://doi.org/10.1101/2024.10.24.24315748

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted October 24, 2024.
Download PDF
Data/Code
Email
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
Anna Brandt, Konrad Klinghammer, Christoph Schultheiss, Lisa Paschold, Claudia Wickenhauser, Marcus Bauer, Anna Bergqvist, Dennis Hahn, Philippe Schafhausen, Mareike Tometten, Markus Blaurock, Henrike Barbara Zech, Chia-Jung Busch, Andreas Dietz, Urs Müller-Richter, Jürgen Alt, Andreas Boehm, Simone Kowoll, Jörg Steighardt, Alexander Lasch, Ingunn Hagen Westgaard, Marita Westhrin, Alexander Stein, Axel Hinke, Mascha Binder
medRxiv 2024.10.24.24315748; doi: https://doi.org/10.1101/2024.10.24.24315748
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area